Literature DB >> 2884455

Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants.

P Hanlon, L Hanlon, V Marsh, P Byass, F Shenton, M Hassan-King, O Jobe, H Sillah, R Hayes, B H M'Boge.   

Abstract

A randomised, controlled trial of bovine rotavirus vaccine was undertaken in Gambian infants. Three doses were administered, from the age of ten weeks, concurrently with oral or killed polio vaccine. Prevaccination rotavirus neutralising antibody levels were high. 84/185 infants (45%) showed an increase in neutralising antibody titre after receiving rotavirus vaccine, compared with 20/91 (22%) unvaccinated infants. Clinical rotavirus infection was detected in 24/78 (31%) children in the rotavirus/oral polio group, 34/83 (41%) children in the placebo/oral polio group, and 23/92 (25%) children in the rotavirus/killed polio group, giving an overall vaccine efficacy of 33% (95% CI 4-53%). RIT 4237 did not appear to reduce the severity of clinical infections. Most cases (92%) were caused by rotaviruses with short RNA electropherotypes. Serological responses to rotavirus vaccination appeared unaffected by the concurrent administration of oral polio vaccine. Lower types 1 and 3 polio antibody levels were found in children who received oral polio and rotavirus vaccines but the differences were not statistically significant.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Antibodies; Antibody Formation--analysis; Biology; Delivery Of Health Care; Developing Countries; English Speaking Africa; Evaluation; Examinations And Diagnoses; Gambia; Health; Health Services; Immunity; Immunization; Immunologic Factors; Laboratory Examinations And Diagnoses; Medicine; Physiology; Preventive Medicine; Primary Health Care; Vaccination--administraction and dosage; Western Africa

Mesh:

Substances:

Year:  1987        PMID: 2884455     DOI: 10.1016/s0140-6736(87)90649-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

1.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 3.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

Review 4.  Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization.

Authors:  N A Cunliffe; P E Kilgore; J S Bresee; A D Steele; N Luo; C A Hart; R I Glass
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 5.  Performance of rotavirus vaccines in developed and developing countries.

Authors:  Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal:  Hum Vaccin       Date:  2010-07

6.  Comparison of immunoglobulin A (IgA), IgG, and IgM enzyme-linked immunosorbent assays, plaque reduction neutralization assay, and complement fixation in detecting seroresponses to rotavirus vaccine candidates.

Authors:  K Midthun; L Z Pang; J Flores; A Z Kapikian
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

Review 7.  Rotavirus vaccines: an overview.

Authors:  Penelope H Dennehy
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  Should the human microbiome be considered when developing vaccines?

Authors:  Rosana B R Ferreira; L Caetano M Antunes; B Brett Finlay
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

Review 9.  Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine.

Authors:  Myron M Levine
Journal:  BMC Biol       Date:  2010-10-04       Impact factor: 7.431

10.  Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis.

Authors:  Johnie Rose; Rachael L Hawthorn; Brook Watts; Mendel E Singer
Journal:  BMJ       Date:  2009-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.